📄 medicine

Association Between Triglyceride-Glucose Index and Mortality Risk in Cancer Survivors — An Analysis Based on NHANES 1999–2018 Data

This study analyzes NHANES data from 1999–2018 to reveal that the triglyceride-glucose (TyG) index exhibits a threshold effect on mortality among cancer survivors, with risks decreasing below specific levels (8.24–8.39) but increasing for cardiovascular and diabetes-related deaths at higher levels, suggesting it is a valuable prognostic marker for targeted interventions.

Original authors: Baoyi Zou, Yanling Lin, Haobo Huang, Yiqun Huang

Published 2026-07-02

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Baoyi Zou, Yanling Lin, Haobo Huang, Yiqun Huang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your body as a bustling city. In this city, sugar (glucose) and fat (triglycerides) are the main fuel supplies. Usually, the city runs smoothly, but sometimes the traffic gets jammed, and the fuel doesn't get to where it needs to go. This traffic jam is called insulin resistance.

To measure how bad this traffic jam is, doctors usually need a complicated, expensive test. But this study introduces a simpler "traffic report" called the TyG Index. It's like a quick weather report for your metabolism, calculated just by looking at your fasting sugar and fat levels.

The researchers took a massive look at data from nearly 2,140 cancer survivors in the US (from 1999 to 2018) to see how this "traffic report" predicts who might get sick or pass away later in life. Here is what they found, explained simply:

1. The "Goldilocks" Zone (The Threshold Effect)

The biggest discovery is that the TyG index isn't just "higher is bad" or "lower is good." It's more like a thermostat.

Too Low: If the index is too low, it might mean the body is running on empty, lacking the energy reserves needed to fight off illness.
Too High: If the index is too high, it means the "fuel" is clogging the pipes, causing inflammation and damage to the heart and blood vessels.
Just Right: The study found a specific "sweet spot" (a threshold) for cancer survivors.
- For dying from any cause, the sweet spot is around 8.39. Below this number, having a slightly higher TyG index actually seemed to protect people (perhaps because they had enough energy reserves). But once you cross 8.39, that protection vanishes, and the risk goes up.
- For dying specifically from cancer, the sweet spot is around 8.24. Below this, a higher index was linked to lower cancer death rates. Above it, the benefit disappeared.

The Analogy: Think of the TyG index like the water level in a boat.

If the water is too low (too low TyG), the boat might run aground (lack of energy/nutrition).
If the water is just right (8.24–8.39), the boat floats perfectly.
If the water gets too high (too high TyG), the boat starts to sink (metabolic damage).

2. Different Risks for Different "Enemies"

The study showed that the TyG index acts differently depending on what you are worried about:

Heart Disease (The Engine): For heart-related deaths, the TyG index is a straight line. The higher it goes, the higher the risk. There is no "safe" high zone here. It's like a car engine: the more sludge (fat/sugar) in the fuel, the more likely the engine is to break.
Diabetes (The Fuel System): This had a sharp "cliff." Below a certain point (8.75), higher TyG was actually linked to lower risk. But once you cross that cliff, the risk of dying from diabetes shoots up dramatically.
High Blood Pressure: The TyG index didn't seem to have a clear, independent link to death from high blood pressure. It was like trying to hear a whisper in a noisy room; other factors were too loud to tell if the TyG index was the cause.

3. Not All Cancers Are the Same

The researchers looked at different types of cancer survivors, and the "traffic report" told different stories for different cities:

Skin Cancer Survivors: For them, a higher TyG index was linked to a lower risk of dying from cancer, but a higher risk of heart trouble. It's like having a strong immune system (good for fighting the cancer) but a clogged heart (bad for the engine).
Female Reproductive Cancers: Here, a moderate TyG level was protective, but if it got too high, it seemed to help the cancer grow instead of fighting it.
Urinary/Reproductive Cancers: For these survivors, the TyG index didn't predict cancer death at all, but it was a very strong warning sign for heart disease.

4. Who Does This Matter Most?

The study found that this "traffic report" is most useful for specific groups:

Older adults (60+): The protective effect of a moderate TyG level was stronger in older people.
Women: The link between TyG and heart risk was stronger in women.
Heavy Smokers: The usual patterns were a bit fuzzier for heavy smokers.

The Bottom Line

The paper concludes that the TyG index is a simple, cheap, and non-invasive tool to check the health of cancer survivors.

The Main Advice from the Study:
If you are a cancer survivor, keeping your TyG index in that "Goldilocks" zone (between 8.24 and 8.39) appears to be the safest bet to lower the risk of dying from cancer or any other cause. If your number is higher than that, the study suggests that targeted interventions (like managing sugar and fat levels) are needed to lower the risk of heart and diabetes-related deaths.

Note: The authors emphasize that this is an observation of data, not a proof of cause-and-effect, but the patterns are strong and consistent across different checks.

Technical Summary: Association Between Triglyceride-Glucose Index and Mortality Risk in Cancer Survivors

Problem Statement
Cancer survivors represent a growing population with elevated risks for all-cause mortality, cardiovascular disease, and metabolic disorders. While insulin resistance is a known driver of poor prognosis, traditional markers like HOMA-IR are cumbersome for large-scale screening. The triglyceride-glucose (TyG) index, a surrogate for insulin resistance, has been linked to various metabolic and cancer outcomes in the general population. However, its specific dose-response relationship, non-linear threshold effects, and heterogeneity across different cancer types regarding mortality in cancer survivors remain unclear. This study addresses the gap in evidence regarding whether the TyG index serves as a reliable prognostic marker for cancer survivors and identifies specific risk intervals for clinical intervention.

Methodology
This cross-sectional analysis utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999–2018.

Population: The study included 2,139 cancer survivors (weighted population: ~19.55 million) aged 20 and older. Participants were excluded if they lacked data on fasting triglycerides, fasting glucose, cancer diagnosis, or survival outcomes.
Exposure: The TyG index was calculated using the formula: $\ln[\text{fasting triglycerides (mg/dL)} \times \text{fasting glucose (mg/dL)} / 2]$ .
Outcomes: Primary outcomes included all-cause mortality, cancer-specific mortality, and cardiometabolic mortality (cardiovascular disease [CVD], diabetes, and hypertension-related). Mortality data were linked to the National Death Index through December 31, 2019.
Statistical Analysis:
- Data Handling: Multiple imputation by chained equations (MICE) was used to handle missing covariates (e.g., BMI, alcohol consumption, poverty income ratio).
- Models: Kaplan–Meier curves and Cox proportional hazards models were employed to assess associations.
- Non-linearity & Thresholds: Restricted cubic spline regression (3 knots) assessed dose-response relationships. Piecewise linear regression models identified inflection points (thresholds) where the association direction or magnitude changed.
- Adjustment: Models were adjusted for sociodemographics (age, sex, race, education, income), lifestyle factors (smoking, alcohol), and clinical comorbidities (BMI, diabetes, hypertension, hyperlipidemia, CVD).
- Robustness: Sensitivity analyses excluded participants who died within the first two years to mitigate reverse causation. Subgroup analyses were conducted by cancer type (skin, female reproductive, urogenital) and participant characteristics.

Key Results
The study identified distinct, outcome-specific associations between the TyG index and mortality, characterized by non-linear threshold effects:

All-Cause Mortality:
- A significant non-linear association was observed with a threshold at TyG = 8.39.
- Below 8.39: Increasing TyG was associated with a reduced risk of all-cause mortality (HR = 0.534 per unit increment).
- Above 8.39: The protective effect vanished, with no significant association observed (HR = 1.000).
- In quartile analysis, the highest TyG group (Q4, >9.15) showed a significantly lower risk compared to the reference (Q2) in the fully adjusted model (HR = 0.83).
Cancer-Specific Mortality:
- A threshold effect was identified at TyG = 8.24.
- Below 8.24: Increasing TyG was significantly associated with reduced cancer-specific mortality (HR = 0.249).
- Above 8.24: The protective effect disappeared (HR = 0.883, non-significant).
- Quartile analysis suggested that the highest TyG group (Q4) had a lower risk compared to Q2 (HR = 0.68), though the trend was marginally significant.
Cardiometabolic Mortality:
- CVD-Related Mortality: The TyG index showed a stable, positive linear association with increased CVD mortality risk (HR = 1.15 per unit increment). No significant threshold effect was found.
- Diabetes-Related Mortality: A threshold effect was observed at TyG = 8.75. Below this, higher TyG was protective; above it, higher TyG significantly increased mortality risk (HR = 2.142).
- Hypertension-Related Mortality: No significant independent linear or threshold association was found in the fully adjusted model, though high TyG quartiles showed increased risk in unadjusted or partially adjusted analyses.
Heterogeneity and Subgroups:
- Cancer Type: The association patterns varied by cancer site. Skin cancer survivors showed a bidirectional protective effect for all-cause and cancer mortality but increased CVD risk. Female reproductive cancer survivors showed a protective effect for all-cause mortality but a pro-tumor effect at high TyG levels for cancer-specific mortality. Urogenital cancer survivors showed no independent prognostic value for tumor outcomes, only for CVD risk.
- Demographics: The protective effect of higher TyG on all-cause mortality was more pronounced in individuals aged ≥60, females, and those with BMI ≥30.0 kg/m². The association was modified by smoking status and alcohol consumption.

Key Contributions

Threshold Identification: The study is the first to systematically identify specific TyG thresholds (8.24 for cancer-specific and 8.39 for all-cause mortality) that delineate a "protective zone" from a "risk zone" in cancer survivors.
Bidirectional Prognostic Value: It demonstrates that the TyG index acts as a bidirectional marker: moderate elevation may reflect sufficient metabolic reserve and nutritional status (protective), while excessive elevation indicates glucolipotoxicity and inflammation (harmful).
Cancer-Type Specificity: The analysis reveals that the prognostic utility of TyG is heterogeneous, depending on the tumor's metabolic dependence (e.g., insulin/IGF-1 signaling vs. gene mutations).
Methodological Rigor: The use of multiple imputation, complex survey weights, and rigorous sensitivity analyses (excluding early deaths) strengthens the validity of the findings.

Significance and Claims
The authors claim that the TyG index is a practical, non-invasive, and low-cost tool for metabolic risk stratification in cancer survivors. The study suggests that maintaining the TyG index within the optimal range of 8.24–8.39 may reduce the risks of all-cause and cancer-specific mortality. Conversely, for patients with elevated TyG levels, targeted interventions to improve insulin resistance and regulate glucose/lipids are necessary to mitigate cardiometabolic mortality risks.

The paper concludes that these findings provide evidence-based support for precision metabolic management in cancer rehabilitation. However, the authors modestly note limitations, including the observational nature of the study (precluding causal inference), the lack of data on tumor stage and treatment regimens, and the restriction to a US adult population, which warrants caution in generalizing to other demographics.